IPRIPR2022-01515Terminated-Adverse Judgment
InvaGen Pharmaceuticals, Inc. et al.v.Bayer Pharma AG et al.
IPR challenge of US 10828310.
Type
IPR
Filed
Sep 8, 2022
Instituted
Oct 19, 2022
Decided
Jan 12, 2026
Patent
Application
16264032
Inventor
Nancy Cook Bruns et al
Granted
Nov 10, 2020
01
Timeline
3 milestones
2022-09-08Petition filed
2022-10-19Institution
2026-01-12Terminated
02
Parties & counsel
Petitioner
InvaGen Pharmaceuticals, Inc. et al.
Counsel
Seth, Nealet al
Patent Owner
Bayer Pharma AG et al.
Counsel
Grossman, Dovet al
03
Docket
Documents are mirrored from the PTAB e-file system. Filer is as stated on the face of the filing.
SOURCE · USPTO PTAB E2EView on Unified Patents →